{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:11:25Z","timestamp":1785298285670,"version":"3.55.0"},"reference-count":29,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.3233\/jhd-170283","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T11:46:15Z","timestamp":1521200775000},"page":"167-173","source":"Crossref","is-referenced-by-count":48,"title":["Cannabinoids for Treatment of Dystonia in Huntington\u2019s Disease"],"prefix":"10.1177","volume":"7","author":[{"given":"Carsten","family":"Saft","sequence":"first","affiliation":[{"name":"Department of Neurology, Huntington Centre NRW, Ruhr-University Bochum, St. Josef-Hospital, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Maria","family":"von Hein","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huntington Centre NRW, Ruhr-University Bochum, St. Josef-Hospital, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"L\u00fccke","sequence":"additional","affiliation":[{"name":"Department of Neuropaediatrics, University Children\u2019s Hospital, Ruhr University, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Thiels","sequence":"additional","affiliation":[{"name":"Department of Neuropaediatrics, University Children\u2019s Hospital, Ruhr University, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Peball","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atbin","family":"Djamshidian","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Heim","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Seppi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JHD-170283_ref1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nbd.2016.08.015","article-title":"Symptom heterogeneity in Huntington\u2019s disease correlates with neuronal degeneration in the cerebral cortex","volume":"96","author":"Mehrabi","year":"2016","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10.3233\/JHD-170283_ref2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.23953","article-title":"Pharmacologic approaches to the treatment of Huntington\u2019s disease","volume":"27","author":"Venuto","year":"2012","journal-title":"Mov Disord"},{"key":"10.3233\/JHD-170283_ref3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2377-6-11","article-title":"Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington\u2019s Disease patients: A case series","volume":"6","author":"Saft","year":"2006","journal-title":"BMC Neurol"},{"issue":"2","key":"10.3233\/JHD-170283_ref4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11920-017-0759-9","article-title":"Juvenile Huntington\u2019s disease: Diagnostic and treatment considerations for the psychiatrist","volume":"19","author":"Quigley","year":"2017","journal-title":"Curr Psychiatry Re"},{"issue":"8","key":"10.3233\/JHD-170283_ref5","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/mds.25422","article-title":"Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington\u2019s disease","volume":"28","author":"Hart","year":"2013","journal-title":"Mov Disord"},{"issue":"21","key":"10.3233\/JHD-170283_ref6","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2174\/138161206777698693","article-title":"Pharmacological management of Huntington\u2019s disease: An evidence-based review","volume":"12","author":"Bonelli","year":"2006","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.3233\/JHD-170283_ref7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/1531-8257(199901)14:1<95::AID-MDS1016>3.0.CO;2-8","article-title":"Dystonia in Huntington\u2019s disease: Prevalence and clinical characteristics","volume":"14","author":"Louis","year":"1999","journal-title":"Mov Disord"},{"issue":"9","key":"10.3233\/JHD-170283_ref8","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/ene.13349","article-title":"Clinical characterization of dystonia in adult patients with Huntington\u2019s disease","volume":"24","author":"van de Zande","year":"2017","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.3233\/JHD-170283_ref9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14656560903426171","article-title":"Treatment strategies for dystonia","volume":"11","author":"Cloud","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.3233\/JHD-170283_ref10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fneur.2015.00177","article-title":"A prospective pilot trial for pallidal deep brain stimulation in Huntington\u2019s disease","volume":"6","author":"Wojtecki","year":"2015","journal-title":"Front Neurol"},{"issue":"3","key":"10.3233\/JHD-170283_ref11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.26142","article-title":"The therapeutic potential of cannabinoids for movement disorders","volume":"30","author":"Kluger","year":"2015","journal-title":"Mov Disord"},{"issue":"17","key":"10.3233\/JHD-170283_ref12","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1212\/WNL.0000000000000363","article-title":"Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"82","author":"Koppel","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.3233\/JHD-170283_ref13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","article-title":"Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the guideline development subcommittee of the American Academy of Neurology","volume":"79","author":"Armstrong","year":"2012","journal-title":"Neurology"},{"issue":"6","key":"10.3233\/JHD-170283_ref14","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/1531-8257(199911)14:6<1038::AID-MDS1024>3.0.CO;2-7","article-title":"Nabilone increases choreatic movements in Huntington\u2019s disease","volume":"14","author":"Muller-Vahl","year":"1999","journal-title":"Mov Disord"},{"issue":"4","key":"10.3233\/JHD-170283_ref15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1176\/jnp.2006.18.4.553","article-title":"Nabilone could treat chorea and irritability in Huntington\u2019s disease","volume":"18","author":"Curtis","year":"2006","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"7","key":"10.3233\/JHD-170283_ref16","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","article-title":"A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease","volume":"263","author":"Lopez-Sendon Moreno","year":"2016","journal-title":"J Neurol"},{"issue":"3","key":"10.3233\/JHD-170283_ref17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in Huntington\u2019s disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"issue":"13","key":"10.3233\/JHD-170283_ref18","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.2174\/13816128113199990434","article-title":"Therapeutic potential of cannabinoids in neurodegenerative disorders: A selective review","volume":"20","author":"Velayudhan","year":"2014","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.3233\/JHD-170283_ref19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1155\/2013\/705373","article-title":"The pathophysiology and pharmacological treatment of Huntington disease","volume":"26","author":"Pidgeon","year":"2013","journal-title":"Behav Neurol"},{"issue":"15","key":"10.3233\/JHD-170283_ref20","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/mds.22809","article-title":"A pilot study using nabilone for symptomatic treatment in Huntington\u2019s disease","volume":"24","author":"Curtis","year":"2009","journal-title":"Mov Disord"},{"issue":"3","key":"10.3233\/JHD-170283_ref21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington\u2019s disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington\u2019s disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"issue":"3","key":"10.3233\/JHD-170283_ref22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0306-4522(93)90352-G","article-title":"Loss of cannabinoid receptors in the substantia nigra in Huntington\u2019s disease","volume":"56","author":"Glass","year":"1993","journal-title":"Neuroscience"},{"issue":"3","key":"10.3233\/JHD-170283_ref23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0091-3057(91)90357-8","article-title":"Assay of plasma cannabidiol by capillary gas chromatography\/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"10.3233\/JHD-170283_ref24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/157488912798842278","article-title":"Cannabinoids: Novel medicines for the treatment of Huntington\u2019s disease","volume":"7","author":"Sagredo","year":"2012","journal-title":"Recent Pat CNS Drug Discov"},{"issue":"6","key":"10.3233\/JHD-170283_ref25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.12998\/wjcc.v5.i6.234","article-title":"Bilateral renal cortical necrosis associated with smoking synthetic cannabinoids","volume":"5","author":"Mansoor","year":"2017","journal-title":"World J Clin Cases"},{"issue":"4","key":"10.3233\/JHD-170283_ref26","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s13311-015-0367-5","article-title":"Cannabinoids and tremor induced by motor-related disorders: Friend or foe?","volume":"12","author":"Arjmand","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.3233\/JHD-170283_ref27","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/jpet.116.232132","article-title":"Tolerance to the diuretic effects of cannabinoids and cross-tolerance to a kappa-opioid agonist in THC-treated mice","volume":"358","author":"Chopda","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.3233\/JHD-170283_ref28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1124\/jpet.112.199331","article-title":"Diuretic effects of cannabinoids","volume":"344","author":"Paronis","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"10.3233\/JHD-170283_ref29","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/jnnp-2013-307343","article-title":"Neuropsychiatric symptoms in a European Huntington\u2019s disease cohort (REGISTRY)","volume":"85","author":"van Duijn","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-170283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:57:25Z","timestamp":1777453045000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-170283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":29,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jhd-170283","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}